Analyst firms · H.C. Wainwright · PRME
H.C. Wainwright PRME price target and rating history
Prime Medicine Inc. (PRME) · Health Care
H.C. Wainwright rates Prime Medicine Inc. (PRME) Buy with a $8 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on PRME since May 2024, including 1 upgrade and 1 downgrade. Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50. H.C. Wainwright's $8 is 6% below that.
- Current rating
- Buy
- Price target
- $8
- Median target, all firms
- $8.50
- Actions on PRME
- 3
H.C. Wainwright price target on PRME
Every H.C. Wainwright rating on PRME
- Jun 29, 2026
- May 20, 2025
- May 20, 2024
How other firms rate PRME
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $7 | Aug 25, 2026 |
| BMO Capital Markets | Outperform | $9 | Aug 19, 2026 |
| H.C. Wainwright | Buy | $8 | Jun 29, 2026 |
| Oppenheimer | Outperform | $11 | Mar 12, 2026 |
Questions about H.C. Wainwright and PRME
- What is H.C. Wainwright's price target for PRME?
- H.C. Wainwright's latest stated price target for Prime Medicine Inc. (PRME) is $8, from its action on Jun 29, 2026.
- What is H.C. Wainwright's rating on PRME?
- H.C. Wainwright rates PRME Buy, a bullish rating, as of Jun 29, 2026.
- When did H.C. Wainwright last change its view on PRME?
- On Jun 29, 2026, H.C. Wainwright upgrades to Buy from Neutral, price target $8.
- How does H.C. Wainwright's PRME target compare with other analysts?
- Across 4 firms with a PRME price target in the last 12 months, the median target is $8.50. H.C. Wainwright's $8 is 6% below that.
More PRME rating histories
All H.C. Wainwright ratingsPRME news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.